❓WHAT HAPPENED: NYU Langone Health announced it will permanently discontinue its transgender “treatment” program for minors.
👤WHO WAS INVOLVED: NYU Langone Health, the Trump administration, and children who faced being transitioned at the hospital.
📍WHEN & WHERE: The decision was announced in Manhattan, New York, following regulatory pressures.
💬KEY QUOTE: “Given the recent departure of our medical director, coupled with the current regulatory environment, we made the difficult decision to discontinue our Transgender Youth Health Program.” – NYU Langone spokesman
🎯IMPACT: The hospital will redirect minors to other local facilities.
NYU Langone Health will permanently shut down its transgender “treatment” program for minors, citing regulatory pressure and leadership changes after the Trump administration threatened to withdraw federal funding from hospitals transitioning children.
“Given the recent departure of our medical director, coupled with the current regulatory environment, we made the difficult decision to discontinue our Transgender Youth Health Program,” a spokesman for NYU Langone said in a statement. The hospital said it would support affected patients during the transition and emphasized that its pediatric mental health services will remain in place.
The medical center has updated its website, replacing the name “Transgender Youth Health Program” with “Gender & Sexuality Service.” While counseling services will continue, minors seeking hormone treatments will be referred to other providers.
The decision follows policy actions by President Donald J. Trump aimed at restricting gender-affirming care for minors. In January 2025, Trump signed an executive order directing federal agencies to withhold funding from institutions that provide the “chemical and surgical mutilation” of children. The policy seeks to block federal support for puberty blockers, cross-sex hormones, and certain surgeries for individuals under 19. The administration has also moved to roll back prior federal guidance expanding gender identity protections in healthcare and to restrict transition-related coverage under federal employee health plans.
NYU Langone is not alone. Baystate Health, the largest healthcare system in western Massachusetts, announced it would stop prescribing hormone therapies to minors, pointing to the evolving regulatory landscape and the need to safeguard Medicaid and Medicare funding, which covers a large share of its patients. “This decision offers patients the specialized expertise and continuity of care they need and deserve,” a spokesman said.
Join Pulse+ to comment below, and receive exclusive e-mail analyses.